CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a company leading the discovery and development of targeted therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in two upcoming conferences:
